AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15180622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 2102
Study 15180622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 11678394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker with rate drop response algorithm programmed to ON
Number of subjects: 50
Study 11678394 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacemaker programmed to OFF
Number of subjects: 50
Study 9510488 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal left ventricular systolic function (group A)
Number of subjects: 240
Study 9510488 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular systolic dysfunction (group B)
Number of subjects: 240
Study 7802219 — intervention group
Group type: EXPERIMENTAL
Intervention: Single medial injection using prilocaine 3% with felypressin
Number of subjects: 107
Study 7802219 — intervention group
Group type: COMPARATOR
Intervention: Two injections using prilocaine 3% with felypressin
Number of subjects: 107
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day carprofen
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day carprofen
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day carprofen
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day carprofen
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen concentrations greater than 10 micrograms/ml
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen concentrations below 1.9 micrograms/ml
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (various doses)
Number of subjects: 38
Study 3293874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (up to 600 mg daily)
Number of subjects: 38
Study 31992356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-enhanced version of the Strengthening Families Program (SFP-Mind)
Number of subjects: 216
Study 31992356 — intervention group
Group type: COMPARATOR
Intervention: Standard Strengthening Families Program 10-14 (SFP 10-14)
Number of subjects: 216
Study 31622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 11100
Study 31622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 11100
Study 31622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning Label
Number of subjects: 11100
Study 31622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 11100
Study 31622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Intakes
Number of subjects: 11100
Study 27590364 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-enhanced cognitive remediation training (CR-CM; n=19)
Number of subjects: 40
Study 27590364 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive remediation training (CR-S; n=21)
Number of subjects: 40
Study 25881455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuanhuang No.1 Recipe (CHR), 400 mL each time, one dose per day for 24 weeks
Number of subjects: 60
Study 25881455 — intervention group
Group type: COMPARATOR
Intervention: Losartan Potassium, 50-100 mg per day for 24 weeks
Number of subjects: 60
Study 23769179 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (5.0-10mg initiated, increased up to 40mg/day)
Number of subjects: 1147
Study 23769179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ARBs allowed)
Number of subjects: 1147
Study 21821220 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice with an instructional video (group A)
Number of subjects: 58
Study 21821220 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice with supervision by an expert instructor (group B)
Number of subjects: 58
Study 21821220 — intervention group
Group type: COMPARATOR
Intervention: Independent practice (group C)
Number of subjects: 58
Study 19820916 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 67
Study 19820916 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 67
Study 19820916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACI and Microfracture
Number of subjects: 67
Study 17213238 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT‐A) 500 units injected into the pectoralis major and biceps brachii on the hemiplegic side
Number of subjects: 17
Study 17213238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15656877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 15656877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11871364 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta2-agonist (salbutamol, n=41)
Number of subjects: 128
Study 11871364 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta2-agonist (formoterol, n=46)
Number of subjects: 128
Study 11871364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 128
Study 9697913 — intervention group
Group type: COMPARATOR
Intervention: Group A (no drain)
Number of subjects: 200
Study 9697913 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (drain)
Number of subjects: 200
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of immunoreactive IL-6
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of C-reactive protein (CRP)
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of alpha 1-antitrypsin (alpha 1AT)
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of acid alpha 1-glycoprotein (orosomucoid; OM)
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of beta 2-microglobulin (beta 2M)
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of thymidine kinase
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high levels of both beta 2M and alpha 1AT or IL-6
Number of subjects: 210
Study 7530507 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vs raised serum IL-6 levels
Number of subjects: 210
Study 2131924 — intervention group
Group type: EXPERIMENTAL
Intervention: clebopride
Number of subjects: 30
Study 2131924 — intervention group
Group type: COMPARATOR
Intervention: domperidone
Number of subjects: 30
Study 419955 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB)
Number of subjects: 30
Study 419955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31255302 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI); n=12
Number of subjects: 23
Study 31255302 — intervention group
Group type: COMPARATOR
Intervention: Sleep Monitoring (SM); n=11
Number of subjects: 23
Study 28052790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient hand-hygiene intervention
Number of subjects: 0
Study 28052790 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 24621065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc daily for 12 weeks
Number of subjects: 50
Study 24621065 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 50
Study 23909679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol treatment
Number of subjects: 22
Study 23909679 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 23909679 — intervention group
Group type: COMPARATOR
Intervention: Patients with venous malformations
Number of subjects: 22
Study 21792626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole, Fulvestrant, and Gefitinib (AFG)
Number of subjects: 15
Study 21792626 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole and Fulvestrant
Number of subjects: 15
Study 19781069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transinguinal preperitoneal technique with soft mesh
Number of subjects: 300
Study 19781069 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 300
Study 16733158 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary surgery
Number of subjects: 50
Study 16733158 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary surgery
Number of subjects: 50
Study 15223416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 20
Study 15223416 — intervention group
Group type: COMPARATOR
Intervention: Thoracic sympathectomy (TS)
Number of subjects: 20
Study 11359594 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with intravenous propofol sedation (SA)
Number of subjects: 40
Study 11359594 — intervention group
Group type: COMPARATOR
Intervention: Inhalational sevoflurane anaesthesia (IA)
Number of subjects: 40
Study 9304087 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream (100 mg/day for 7 days)
Number of subjects: 105
Study 9304087 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin (2 g/day for 7 days)
Number of subjects: 105
Study 8389108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1,000 micrograms/day for 2 weeks
Number of subjects: 10
Study 8389108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3625417 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk with mineral supplementation (high mineral formula)
Number of subjects: 50
Study 3625417 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk with powdered fortifier
Number of subjects: 50
Study 3625417 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented human milk
Number of subjects: 50
Study 3625417 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at follow-up (44 weeks postconceptional age)
Number of subjects: 50
Study 31932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple dressing
Number of subjects: 394
Study 31932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue-as-a-dressing
Number of subjects: 394
Study 31932387 — intervention group
Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 394
Study 29108797 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor plus NRTI group (lopinavir 400 mg with ritonavir 100 mg, twice per day plus two or three clinician-selected NRTIs)
Number of subjects: 1277
Study 29108797 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor plus raltegravir group (lopinavir plus raltegravir 400 mg twice per day)
Number of subjects: 1277
Study 29108797 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy group (lopinavir monotherapy plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96)
Number of subjects: 1277
Study 27322832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with information about the benefits of organ donation
Number of subjects: 0
Study 27322832 — intervention group
Group type: COMPARATOR
Intervention: Video without information about the benefits of organ donation
Number of subjects: 0
Study 25357218 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy (3 sessions at 15, 30, and 45 days after infliximab infusion)
Number of subjects: 38
Study 25357218 — intervention group
Group type: COMPARATOR
Intervention: Control (simple follow-up)
Number of subjects: 38
Study 25357218 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy
Number of subjects: 38
Study 22838004 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task (PASAT)
Number of subjects: 14
Study 22838004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 14
Study 22838004 — intervention group
Group type: COMPARATOR
Intervention: Control (HS alone)
Number of subjects: 14
Study 22838004 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT
Number of subjects: 14
Study 22838004 — intervention group
Group type: EXPERIMENTAL
Intervention: PASAT
Number of subjects: 14
Study 20415897 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 0
Study 20415897 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 0
Study 20415897 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 18375318 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐Is (ramipril, 1.25 mg twice a day from the day after the operation)
Number of subjects: 34
Study 18375318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACE‐Is)
Number of subjects: 34
Study 15262194 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐alpha‐tocopherol 750 IU (group AE)
Number of subjects: 22
Study 15262194 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20mg with placebo (group AP)
Number of subjects: 22
Study 12577430 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoreqing (NRQ) oral liquid
Number of subjects: 0
Study 12577430 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoreqing (NRQ) oral liquid plus western medicine
Number of subjects: 0
Study 12577430 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 0
Study 9701524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.d. (group PMC 500)
Number of subjects: 163
Study 9701524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.d. (group PMC 250)
Number of subjects: 163
Study 8027495 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate
Number of subjects: 12
Study 8027495 — intervention group
Group type: COMPARATOR
Intervention: Baking soda
Number of subjects: 12
Study 2589358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 68
Study 2589358 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus Gentamicin
Number of subjects: 68
Study 922326 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 100
Study 922326 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty (PGVP)
Number of subjects: 100
Study 31954998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg/day
Number of subjects: 372
Study 31954998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg/day
Number of subjects: 372
Study 31954998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 31954998 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 372
Study 31954998 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious TEAEs
Number of subjects: 372
Study 31481813 — intervention group
Group type: EXPERIMENTAL
Intervention: All-acrylic removable partial dentures (RPD)
Number of subjects: 30
Study 31481813 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible removable partial dentures (RPD)
Number of subjects: 30
Study 29036256 — intervention group
Group type: COMPARATOR
Intervention: Oral minocycline HCl extended-release tablets (approximately 1 mg/kg)
Number of subjects: 30
Study 29036256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minocycline foam 4% (4-g maximal-use dose) applied once daily for 21 days
Number of subjects: 30
Study 24336330 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-specific TGFBR2 expression
Number of subjects: 564
Study 24336330 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-specific pSMAD2 levels
Number of subjects: 564
Study 24336330 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFBR2 knockdown in CAFs
Number of subjects: 564
Study 24336330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse model with TGFBR2 knockdown fibroblasts
Number of subjects: 564
Study 23749624 — intervention group
Group type: EXPERIMENTAL
Intervention: PARZIVAR intervention
Number of subjects: 0
Study 23749624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 22141447 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD prevention intervention (computerized decision aid and automated tailored adherence messages)
Number of subjects: 160
Study 22141447 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 160
Study 19221257 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body irradiated with a 0.7-MED of UV-B daily on 10 consecutive days followed by a single dose of 3 MEDs on a small body area
Number of subjects: 98
Study 19221257 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body irradiated with 120 J/m2 solar-simulated radiation for 10 consecutive days, then single-dose UV-B exposure of 3 MEDs on a small body area after 24 hours
Number of subjects: 98
Study 19221257 — intervention group
Group type: COMPARATOR
Intervention: Irradiated with a single UV-B dose of 3 MEDs on a small body area
Number of subjects: 98
Study 19221257 — intervention group
Group type: COMPARATOR
Intervention: Irradiated with a single UV-B dose of 4 MEDs on a small body area
Number of subjects: 98
Study 17033263 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum IGF-I concentrations
Number of subjects: 0
Study 17033263 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxological data evaluation (growth rate and growth)
Number of subjects: 0
Study 14656270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-containing chemotherapy
Number of subjects: 924
Study 14656270 — intervention group
Group type: COMPARATOR
Intervention: Observation following surgery
Number of subjects: 924
Study 11720165 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF movement with hip internal rotation
Number of subjects: 6
Study 11720165 — intervention group
Group type: COMPARATOR
Intervention: Other exercises (not specified)
Number of subjects: 6
Study 9209998 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene haptic IOL
Number of subjects: 156
Study 9209998 — intervention group
Group type: COMPARATOR
Intervention: All PMMA IOL
Number of subjects: 156
Study 7510316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 12.5 mg single dose and 12 weeks treatment up to 37.5 mg daily
Number of subjects: 0
Study 7510316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine in elderly patients
Number of subjects: 0
Study 3774011 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of chemotherapy (cyclophosphamide, 5 mg/kg/day for 6 days iv)
Number of subjects: 507
Study 3774011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 507
Study 3774011 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued chemotherapy for 1 year (for node-positive patients)
Number of subjects: 507
Study 31729625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 52
Study 31729625 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 52
Study 31263526 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 100
Study 31263526 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone
Number of subjects: 100
Study 27458288 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg flat dose) administered twice per week (days 1 and 3) on a 3 weeks on, 1 week off schedule
Number of subjects: 54
Study 25161024 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 13577
Study 25161024 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4
Number of subjects: 13577
Study 25161024 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 13577
Study 23052111 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 72
Study 23052111 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 20658454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-pressure (UHP) angioplasty
Number of subjects: 22
Study 20658454 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Cutting Balloon (PCB) angioplasty
Number of subjects: 22
Study 20467648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 26
Study 20467648 — intervention group
Group type: COMPARATOR
Intervention: No HBO therapy
Number of subjects: 26
Study 16892928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization technique
Number of subjects: 36
Study 16892928 — intervention group
Group type: COMPARATOR
Intervention: Sterile intermittent catheterization technique
Number of subjects: 36
Study 12659243 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized oxygen dissolved in water
Number of subjects: 15
Study 12659243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 15
Study 12659243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10321398 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs who check the accuracy of invitation lists
Number of subjects: 158
Study 10321398 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs who follow up non-attendees for screening
Number of subjects: 158
Study 8876070 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cetirizine (CTZ)
Number of subjects: 210
Study 8876070 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg pseudoephedrine retard (PER)
Number of subjects: 210
Study 8876070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5 mg cetirizine and 120 mg pseudoephedrine retard (COM)
Number of subjects: 210
Study 1362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin or octreotide
Number of subjects: 0
Study 1362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Glypressin
Number of subjects: 0
Study 1362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and nitroglycerin
Number of subjects: 0
Study 1362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive agents
Number of subjects: 0
Study 3925486 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg IV)
Number of subjects: 10